Therapeutic Update on Huntington’s Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Clinical Neurology,Pharmacology
Link
https://link.springer.com/content/pdf/10.1007/s13311-020-00891-w.pdf
Reference144 articles.
1. Harper P. The epidemiology of Huntington’s disease. Hum Genet. 1992;89(4):365—376.
2. Fisher ER, Hayden MR. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov Disord . 2014;29(1):105–114.
3. Evans SJW, Douglas I, Rawlins MD, Wexler NS, Tabrizi SJ, Smeeth L. Prevalence of adult Huntington’s disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry. 2013;84(10):1156–1160.
4. Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, et al. Huntington disease. Nat Rev Dis Primer. 2015;1:15005.
5. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR, International Huntington’s Disease Collaborative Group. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet. 2004;65(4):267–277.
Cited by 47 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Imidazoline receptors as a new therapeutic target in Huntington’s disease: A preclinical overview;Ageing Research Reviews;2024-11
2. Emerging pharmacological approaches for Huntington's disease;European Journal of Pharmacology;2024-10
3. Dalzanemdor (SAGE‐718), a novel, investigational N‐methyl‐D‐aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose‐finding studies in healthy participants and an open‐label study in participants with Huntington's disease;Clinical and Translational Science;2024-07
4. Huntington’s Disease: Latest Frontiers in Therapeutics;Current Neurology and Neuroscience Reports;2024-06-11
5. Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington’s disease;Archives of Pharmacal Research;2024-05-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3